D-二聚体在COVID-19患者深静脉血栓诊断中的效用
该回顾性研究纳入158例确诊COVID-19且同时接受D-二聚体和静脉双功超声检查的患者,其中52例有DVT、106例无DVT。有DVT者急性期D-二聚体水平显著更高,最佳截断值6494 ng/mL的敏感度80.8%、特异度68.9%、阴性预测值88.0%,提示低于该值可能排除DVT。
要点
- COVID-19患者D-二聚体普遍升高,常规标准下全部患者均升高。
- 有DVT者D-二聚体中位数13602 ng/mL,显著高于无DVT者的2880 ng/mL。
- D-二聚体低于6494 ng/mL可能排除DVT,或可减少静脉超声检查需求。
核心结论
- COVID-19患者D-二聚体普遍升高,标准预测标准未能预测DVT。
- D-二聚体低于6494 ng/mL可能排除DVT,或可限制静脉双功超声检查需求。
研究设计与样本
- 回顾性队列研究,纳入2020年3月1日至5月13日经PCR确诊COVID-19且同时接受D-二聚体和静脉双功超声检查的连续住院患者。
- 共1170例COVID-19患者住院,其中158例纳入分析,52例有DVT、106例无DVT。
主要发现
- 两组在性别、年龄、种族或族裔方面无差异,DVT组糖尿病和常规血液透析较少见。
- 两组超过90%患者接受预防性抗凝,但低分子肝素或皮下肝素预防不能预测DVT。
- 常规标准下所有患者急性期D-二聚体均升高,年龄校正标准下158例中154例(97.5%)升高,平均D-二聚体16163±5395 ng/mL。
- DVT组急性期D-二聚体中位数13602 ng/mL(四分位距6616-36543 ng/mL),无DVT组2880 ng/mL(四分位距1030-9126 ng/mL),P < .001。
- 最佳D-二聚体截断值6494 ng/mL区分有无DVT,敏感度80.8%、特异度68.9%、阴性预测值88.0%;校正其他因素后OR 6.12(95%CI 2.79-13.39,P < .001)。
关键数值与推荐
- D-二聚体最佳截断值6494 ng/mL用于区分有无DVT,敏感度80.8%、特异度68.9%、阴性预测值88.0%。
- Wells DVT标准未发现是DVT的显著预测因素。
- 以最佳指标定义的D-二聚体升高在单变量和多变量分析中均为DVT的显著预测因素(OR 6.12,95%CI 2.79-13.39,P < .001)。
临床怎么用
- COVID-19患者D-二聚体普遍升高,不宜仅凭常规升高判断DVT。
- D-二聚体低于6494 ng/mL可能用于排除DVT,或可减少静脉双功超声检查需求。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The objective of this study was to investigate the clinical usefulness of d-dimer in excluding a diagnosis of deep vein thrombosis (DVT) in patients with coronavirus disease (COVID-19) infection, potentially limiting the need for venous duplex ultrasound examination. METHODS: We retrospectively reviewed consecutive patients admitted to our institution with confirmed COVID-19 status by polymerase chain reaction between March 1, 2020, and May 13, 2020, and selected those who underwent both d-dimer and venous duplex ultrasound examination. This cohort was divided into two groups, those with and without DVT based on duplex ultrasound examination. These groups were then compared to determine the value of d-dimer in establishing this diagnosis. RESULTS: A total of 1170 patients were admitted with COVID-19, of which 158 were selected for this study. Of the 158, there were 52 patients with DVT and 106 without DVT. There were no differences in sex, age, race, or ethnicity between groups. Diabetes and routine hemodialysis were less commonly seen in the group with DVT. More than 90% of patients in both groups received prophylactic anticoagulation, but the use of low-molecular-weight heparin or subcutaneous heparin prophylaxis was not predictive of DVT. All patients had elevated acute-phase d-dimer levels using conventional criteria, and 154 of the 158 (97.5%) had elevated levels with age-adjusted criteria (mean d-dimer 16,163 ± 5395 ng/mL). Those with DVT had higher acute-phase d-dimer levels than those without DVT (median, 13,602 [interquartile range, 6616-36,543 ng/mL] vs 2880 [interquartile range, 1030-9126 ng/mL], P < .001). An optimal d-dimer cutoff of 6494 ng/mL was determined to differentiate those with and without DVT (sensitivity 80.8%, specificity 68.9%, negative predictive value 88.0%). Wells DVT criteria was not found to be a significant predictor of DVT. Elevated d-dimer as defined by our optimal metric was a statistically significant predictor of DVT in both univariate and multivariable analyses when adjusting for other factors (odds ratio, 6.12; 95% confidence interval, 2.79-13.39; P < .001). CONCLUSIONS: d-dimer levels are uniformly elevated in patients with COVID-19. Although standard predictive criteria failed to predict DVT, our analysis showed a d-dimer of less than 6494 ng/mL may exclude DVT, potentially limiting the need for venous duplex ultrasound examination.
引用
- Cho ES, McClelland PH, Cheng O, et al. Utility of d-dimer for diagnosis of deep vein thrombosis in coronavirus disease-19 infection. J Vasc Surg Venous Lymphat Disord. 2020. PMID: 32738407. doi:10.1016/j.jvsv.2020.07.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。